Previse develops the Esopredict® molecular test, which utilizes proprietary epigenetic biomarkers to assess the risk of progression from Barrett’s esophagus to esophageal cancer. This test provides personalized guidance for surveillance and treatment decisions, addressing the critical need for early detection in cancer prevention.
Funding
$7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Esophageal cancer often develops from Barrett’s esophagus, a precancerous condition, but current methods for assessing progression risk lack precision, leading to uncertainty in surveillance and treatment decisions. This can result in both under- and over-treatment, impacting patient outcomes and healthcare costs.
Solution
Previse offers Esopredict, a molecular test that utilizes epigenetic biomarkers to provide a personalized risk assessment for patients with Barrett’s esophagus. By analyzing these biomarkers, the test generates an Esoscore report that helps healthcare providers determine the likelihood of progression to esophageal cancer. This enables more informed decisions regarding surveillance intervals, endoscopic interventions, and other treatment strategies. The test aims to improve early detection rates, optimize resource allocation, and ultimately save lives through earlier, more targeted interventions.
Target Audience
The primary users are gastroenterologists and other healthcare providers who manage patients with Barrett’s esophagus, as well as the patients themselves seeking a clearer understanding of their individual risk.
Features
- Proprietary epigenetic biomarkers for risk stratification
- Personalized Esoscore report indicating risk of progression
- Guidance for tailored surveillance and treatment plans
- Designed for use with diverse clinical study populations